 | 
|
| |
|
Titel: Bilder av hjärnan - ett stöd i utredningen av demens (serie: Tema demens) 2009 nr 20 sid 1390-5
|
Referenser:
1. Walstra GJ, Teunisse S, van Gool WA, van Crevel H. Reversible dementia in elderly patients referred to a memory clinic. J Neurol. 1997;244(1):17-22.
2. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1(1):13-21.
3. Frisoni GB. Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools. J Neurol Neurosurg Psychiatry. 2001;70:711-8.
4. Zaknun JJ, Leibhuber F, Schücktanz H. Value of cerebral blood flow quantification in the diagnosis of dementia. Nucl Med Commun. 2008;29:260-9.
5. Pimlott SL, Ebmeier KP. SPECT imaging in dementia. Br J Radiology. 2007;80:S153-S159.
6. Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer´s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19.
7. Demenssjukdomar. En systematisk litteraturöversikt. Stockholm: SBU; 2006. Rapport nr 172.
8. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology. 2000;54:1304-9.
9. Waldemar G, Bruhn P, Kristensen M, Johnsen A, Paulson OB, Lassen NA. Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,l-HMPAO SPECT study. Neurol Neurosurg Psychiatry. 1994;57:285-95.
10. Patwardhan M, McCrory D, Matchar D, Samsa GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET - A meta analysis. Radiology. 2004;231:73-80.
11. Dubois B, Feldman H, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer´s disease: revising the NINCDS-ADRDA criteria. Lancet Neurology. 2007;6:734-46.
12. Rowe C, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging _-amyloid burden in aging and dementia. Neurology. 2007;68:1718-25.
13. Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52(7):1397-403.
14. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer´s disease. Arch Neurol. 2005;62:1728-33.
15. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-60.
16. Drayer BP. Imaging of the aging brain. Part I. Normal findings. Radiology.1988;166:785-96.
17. Lojkowska W, Ryglewicz D, Jedrzejczak T, Sienkiewicz-Jarosz H, Minc S, Jakubowska T, et al. SPECT as a diagnostic tool in the investigation of dementia. J Neurol Sci. 2002;203-204:215-9.
18. Kumar-Singh S, Van Broeckhoven C. Frontotemporal lobar degeneration: current concepts in the light of recent advances. Brain Pathol. 2007;17(1):104-14.
19. Larsson E, Passant U, Sundgren PC, Englund E, Brun A, Lindgren A, et al. Magnetic resonance imaging and histopathology in dementia, clinically of frontotemporal type. Dement Geriatr Cogn Disord. 2000;11(3):123-34.
20. Hodges JR. Frontotemporal dementia (Picks's disease): clinical features and assessment. Neurology. 2001;56:S6-S10.
21. Mosconi L, Tsui W, Herlholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer´s disease, and other dementias. J Nucl Med. 2008;49:390-8.
22. Foster N, Heidebrink J, Clark C, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616-35.
23. Kertesz A, Munoz DG. Primary progressive aphasia and aphasia and Pick complex. J Neurol Sci. 2003;206:97-107.
24. Kipps CM, Davies RR, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRTI visual rating scale. Dement Geriatr Cogn Disord. 2007;23(5):334-42.
25. Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, et al. New and reliable MRTI diagnosis for progressive supranuclear palsy. Neurology. 2005;64(12):2050-5.
26. Josephs KA, Whitwell JL, Dickson DW, Boeve BF, Knopman DS, Petersen RC, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging. 2008;29(2):280-9.
27. Okuda B, Tachibana H, Kawabata K, Takeda M, Sugita M. Cerebral blood flow in corticobasal degeneration and progressive supranuclear palsy. Alzheimer Dis Assoc Disord. 2000;14:46-52.
28. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912-21.
29. Lökk J, Winblad B. Demens - vanlig, svårbehandlad komplikation vid parkinson. Tidig diagnos värdefull - kolinesterashämmare kan ge bättre livskvalitet. Läkartidningen. 2006;103:451-5.
30. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305-13.
31. Hu X, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology. 2000;55:1575-6.
 1390 |
 1391 |
 1392 |
 1393 |
 1394 |
 1395 |